Stock listing
OTC:CASIF CASI Pharmaceuticals, Inc. Stock
Follow CASI Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · OTC:CASIF
$0.10 USD +0.00 (+0.1%)
Close on Nov 20, 2026
- Day range
- $0.10 – $0.10 USDNov 20, 2026
- Volume
- 15,012 sharesNov 20, 2026
- Market cap
- $2.06M USDAt the close on Nov 20, 2026 · price × 20.56M shares outstanding
- 52-week range
- $0.05 – $1.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $223 USDMedian day 700 shares · 6 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:CASIF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.10 | +0.00 | +0.1% | $0.10 | $0.10 | $0.10 | 15,012 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 70 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 10,000 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 2 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 1,575 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 887 | |
| $0.10 | 0.00 | -0.1% | $0.10 | $0.10 | $0.10 | 18,434 | |
| $0.10 | -0.01 | -9.0% | $0.10 | $0.10 | $0.10 | 726 | |
| $0.11 | +0.01 | +9.9% | $0.11 | $0.11 | $0.11 | 709 | |
| $0.10 | +0.00 | +0.1% | $0.10 | $0.10 | $0.10 | 50 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 189 | |
| $0.10 | -0.015 | -12.9% | $0.105 | $0.105 | $0.10 | 145 | |
| $0.115 | -0.015 | -11.8% | $0.133 | $0.133 | $0.115 | 4,892 | |
| $0.13 | +0.013 | +10.7% | $0.13 | $0.13 | $0.13 | 258 | |
| $0.118 | +0.017 | +17.5% | $0.11 | $0.118 | $0.11 | 356 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 252 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 625 | |
| $0.10 | 0.00 | 0.0% | $0.12 | $0.12 | $0.10 | 4,100 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 5,200 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 900 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 500 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 700 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 400 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 700 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 300 | |
| $0.10 | -0.01 | -9.1% | $0.11 | $0.11 | $0.10 | 2,300 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 2,100 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 200 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.13 | $0.11 | 4,500 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 3,000 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 800 | |
| $0.11 | -0.01 | -8.3% | $0.11 | $0.11 | $0.11 | 200 | |
| $0.12 | 0.00 | 0.0% | $0.12 | $0.12 | $0.12 | 1,000 | |
| $0.12 | +0.01 | +9.1% | $0.11 | $0.12 | $0.11 | 3,300 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 50 | |
| $0.11 | -0.01 | -8.3% | $0.11 | $0.11 | $0.11 | 300 | |
| $0.12 | -0.01 | -7.7% | $0.13 | $0.13 | $0.12 | 1,300 | |
| $0.13 | -0.03 | -18.8% | $0.13 | $0.13 | $0.13 | 600 | |
| $0.16 | 0.00 | 0.0% | $0.16 | $0.16 | $0.16 | 0 | |
| $0.16 | +0.03 | +23.1% | $0.13 | $0.16 | $0.13 | 2,800 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 300 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 700 | |
| $0.13 | -0.01 | -7.1% | $0.13 | $0.14 | $0.13 | 400 | |
| $0.14 | +0.01 | +7.7% | $0.13 | $0.14 | $0.13 | 1,700 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 0 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 58 | |
| $0.13 | -0.01 | -7.1% | $0.13 | $0.14 | $0.13 | 2,500 | |
| $0.14 | 0.00 | 0.0% | $0.14 | $0.14 | $0.14 | 0 | |
| $0.14 | +0.01 | +7.7% | $0.14 | $0.14 | $0.14 | 3,000 | |
| $0.13 | -0.01 | -7.1% | $0.14 | $0.14 | $0.13 | 6,300 | |
| $0.14 | -0.01 | -6.7% | $0.14 | $0.14 | $0.14 | 12,200 | |
| $0.15 | 0.00 | 0.0% | $0.15 | $0.15 | $0.15 | 700 | |
| $0.15 | +0.01 | +7.1% | $0.15 | $0.15 | $0.15 | 700 | |
| $0.14 | +0.01 | +7.7% | $0.14 | $0.14 | $0.14 | 1,500 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 0 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 100 | |
| $0.13 | -0.01 | -7.1% | $0.13 | $0.13 | $0.13 | 1,700 | |
| $0.14 | +0.01 | +7.7% | $0.14 | $0.14 | $0.14 | 100 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 0 | |
| $0.13 | -0.01 | -7.1% | $0.13 | $0.13 | $0.13 | 100 | |
| $0.14 | +0.01 | +7.7% | $0.13 | $0.14 | $0.13 | 500 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 0 | |
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 1,200 |
Splits
2 splits since 2010 · OTC:CASIF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-11 | Consolidation |
- Ticker
- OTC:CASIF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest deck · January 2026
Investor Presentation (January 2026)
Investor deck · 28 slides
CASI Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Calls
- 1 call with a replay · 1 with a transcript · latest Mar 12, 2021
- Decks
- 22 decks · latest January 2026
Valuation
EV/sales 1.9× against a median of −11.6×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $38.79M USD
- P/E
- Loss
- EV/sales
- 1.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- 60.0%
- Operating margin
- −191.0%
- Net margin
- −218.6%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- -0.07
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CASI Pharmaceuticals, Inc. · OTC:CASIF | US$2.06M | US$38.79M | n/a | 1.9× | n/a | n/a | −218.6% | n/a | -0.07 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.67M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| PharmaCyte Biotech, Inc. · NASDAQ:PMCB | US$2.25M | −US$15.59M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.97 |
| Modus Therapeutics Holding AB · OMXSTO:MODTX | US$2.23M | US$1.00M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Nuformix PLC · LSE:NFX | US$2.22M | US$1.00M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Medicus Pharma Ltd. · NASDAQ:MDCX | US$2.18M | −US$2.73M | n/a | n/a | n/a | n/a | n/a | n/a | 2.03 |
| Senti Biosciences Holdings, Inc. · NASDAQ:SNTI | US$2.06M | −US$3.49M | n/a | −47.2× | n/a | n/a | n/a | n/a | 2.91 |
| Vectus Biosystems Limited · ASX:VBS | US$2.02M | US$51,064 | 1.9× | n/a | n/a | 1.3× | n/a | 0.2× | n/a |
| Decoy Therapeutics Inc. · NASDAQ:DCOY | US$1.98M | −US$6.19M | n/a | −11.6× | n/a | 0.4× | n/a | 0.0× | 1.28 |
| Genprex, Inc. · NASDAQ:GNPX | US$1.94M | −US$13.41M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.08 |
| Median of the others | US$2.20M | −US$2.85M | 1.9× | −11.6× | 0.5× | −540.4% | 0.0× | 1.63 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.41 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Chunhua Wang | Chief Operating Officer |
| Wei Gao | General Counsel |
| Junping Chen | Chief Medical Officer |
| Kun Qian | Global Controller |
| Wei-Wu He | Executive Chairman |
Board
| Director | Role |
|---|---|
| Wei-Wu He | Executive Chairman |
| Alex Wu | Director |
| Frank Su | Director |
| James Huang | Director |
| Thomas Folinsbee | Director |
| Xuebo Zeng | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| CASI Pharmaceuticals (OTC:CASIF) Q4 2020 Earnings Call | Fri, Mar 12, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | May 15, 2026 · Before open | +7.1% |
| Q3 2025 | Nov 14, 2025 · After close | −5.6% |
| Q2 2025 | Aug 29, 2025 · After close | −0.4% |
| Q1 2025 | May 16, 2025 · Before open | +7.2% |
| Q3 2024 | Nov 15, 2024 · Before open | −9.3% |
| Q2 2024 | Aug 16, 2024 · Before open | 0.0% |
| Q1 2024 | May 14, 2024 | +27.2% |
| Q4 2023 | Mar 28, 2024 · Before open | +20.3% |
| Q3 2023 | Nov 14, 2023 · Before open | +1.1% |
| Q2 2023 | Aug 11, 2023 · Before open | +3.6% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 17, 2023 · Before open | −7.6% |
| Q3 2022 | Nov 14, 2022 · Before open | −4.5% |
| Q2 2022 | Aug 12, 2022 · Before open | −10.8% |
| Q1 2022 | May 12, 2022 · Before open | −6.1% |
| Q4 2021 | Mar 28, 2022 | +9.4% |
| Q3 2021 | Nov 12, 2021 · Before open | +2.9% |
| Q2 2021 | Aug 12, 2021 · Before open | −1.7% |
| Quarter to Mar 31, 2021 | May 13, 2021 · Before open | −2.1% |
| Quarter to Dec 31, 2020 | Mar 30, 2021 | +21.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 28 slides | January 2026 |
| Corporate Update (May 2025) | Corporate update | 21 slides | May 21, 2025 |
| Investor Presentation (August 2022) | Investor deck | 30 slides | August 2022 |
| Investor Presentation (May 2022) | Investor deck | 30 slides | May 2022 |
| Jefferies London Healthcare Conference 2021 | Conference | 29 slides | November 2021 |
| Investor Presentation (September 2021) | Investor deck | 21 slides | September 2021 |
| Investor Presentation (September 2021) | Investor deck | 24 slides | September 2021 |
| Investor Presentation (August 2021) | Investor deck | 37 slides | August 2021 |
| Shareholder Meeting (June 2021) | Shareholder meeting | 37 slides | Jun 15, 2021 |
| Investor Presentation (March 2021) | Investor deck | 12 slides | Mar 12, 2021 |
All 22 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| HCW 22nd Annual Global Investment Conference (September 2020) | Conference | 26 slides | Sep 14, 2020 |
| Investor Presentation (June 2020) | Investor deck | 20 slides | June 2020 |
| Investor Presentation (September 2019) | Investor deck | 13 slides | September 2019 |
| BIO International 2019 | Conference | 20 slides | Jul 14, 2019 |
| Shareholder Meeting (June 2018) | Shareholder meeting | 21 slides | Jun 11, 2018 |
| Investor Presentation (June 2018) | Investor deck | 13 slides | Jun 4, 2018 |
| BIO CEO & Investor Conference 2018 | Conference | 18 slides | Feb 13, 2018 |
| Investor Presentation (October 2017) | Investor deck | 17 slides | October 2017 |
| Rodman & Renshaw 19th Annual Global Investment Conference (September 2017) | Conference | 23 slides | Sep 11, 2017 |
| Shareholder Meeting (June 2017) | Shareholder meeting | 35 slides | Jun 8, 2017 |
| Investor Presentation (November 2014) | Investor deck | 48 slides | Nov 17, 2014 |
| Investor Presentation (May 2014) | Investor deck | 7 slides | May 2014 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.7M | 28.5M | 33.9M | 43.1M | 30.2M | 15.1M | 4.13M | |||
| Cost of revenue | 10.6M | 17.4M | 13.8M | 15.8M | 12.6M | 9.51M | 3.94M | 1.67M | 117.8K | 66.5K |
| Gross profit | 10.1M | 11.1M | 20.1M | 27.3M | 17.6M | 5.63M | 196.0K | -1.67M | -117.8K | -66.5K |
| Research and development | 6.31M | 8.92M | 9.86M | 16.0M | 14.4M | 11.5M | 9.75M | 8.51M | 7.60M | 4.65M |
| Selling, general and administrative | 46.6M | 23.6M | 25.4M | 23.4M | 23.7M | 19.7M | 27.3M | 18.0M | 3.16M | 4.78M |
| Operating income | -45.0M | -39.6M | -25.1M | -34.0M | -41.5M | -52.8M | -40.0M | -26.5M | -10.8M | 9.42M |
| Depreciation and amortization | 1.20M | 1.30M | 2.50M | 1.20M | 500.0K | 600.0K | 2.15M | 1.67M | 117.8K | 66.5K |
| EBITDA | -43.8M | -38.3M | -22.6M | -32.8M | -41.0M | -52.2M | -37.8M | -24.8M | -10.6M | 9.49M |
| Interest expense | 840.0K | 871.0K | 15.0K | 0 | 2.90K | 3.10K | 8.21K | 15.0K | 33.8K | |
| Income before tax | -45.9M | -38.1M | -26.3M | -37.4M | -35.8M | -47.5M | -45.4M | -27.5M | -10.8M | -9.45M |
| Income tax | 0 | -81.0K | 1.98M | 0 | 0 | 15.0K | 33.8K | |||
| Net income | -48.1M | -39.3M | -27.0M | -41.0M | -36.7M | -48.3M | -45.4M | -27.5M | -10.8M | -9.45M |
| Earnings per share, basic | -2.59 | -2.56 | -2.02 | -3.01 | -2.69 | -4.37 | -4.73 | -3.24 | -1.75 | -1.69 |
| Earnings per share, diluted | -2.59 | -2.56 | -2.02 | -3.01 | -2.69 | -4.37 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.63M | 13.5M | 17.1M | 47.1M | 38.7M | 57.1M | 53.6M | 84.2M | 43.5M | 27.1M |
| Short-term investments | 0 | 2.62M | 12.0M | 1.46M | 9.87M | 9.31M | 625.0K | 912.2K | ||
| Receivables | 4.09M | 15.3M | 9.55M | 13.0M | 9.80M | 4.64M | 1.29M | |||
| Inventory | 1.60M | 5.25M | 15.9M | 6.14M | 1.91M | 1.36M | 4.54M | 283.0K | ||
| Current assets | 13.5M | 39.6M | 59.3M | 73.4M | 62.0M | 74.0M | 61.5M | 92.6M | 43.8M | 27.4M |
| Property, plant and equipment | 6.97M | 7.87M | 9.24M | 11.8M | 12.7M | |||||
| Total assets | 25.6M | 53.7M | 75.3M | 96.2M | 138.3M | 127.7M | 102.6M | 113.4M | 45.1M | 27.7M |
| Accounts payable | 1.06M | 2.72M | 4.44M | 3.29M | 2.22M | 3.26M | 5.11M | 968.0K | 2.09M | 1.06M |
| Current liabilities | 49.7M | 36.5M | 16.7M | 17.0M | 13.2M | 7.98M | 7.95M | 3.87M | 5.06M | 1.32M |
| Long-term debt | 18.9M | |||||||||
| Total debt | 19.2M | 18.4M | 18.9M | 1.34M | 4.33M | 3.20M | 2.20M | 1.50M | 1.50M | 1.49M |
| Total liabilities | 62.9M | 51.8M | 51.1M | 29.3M | 30.3M | 24.2M | 8.97M | 3.95M | 6.56M | 6.93M |
| Shareholders' equity | -37.3M | 1.85M | 24.2M | 44.6M | 84.5M | 81.5M | 73.0M | 109.5M | 38.5M | 20.8M |
| Shares outstanding | 20.6M | 15.5M | 13.4M | 13.5M | 14.0M | 13.4M | 9.59M | 8.48M | 6.15M | 5.59M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -20.8M | -29.2M | -20.0M | -21.1M | -26.8M | -25.9M | -23.2M | -28.6M | -6.40M | -6.02M |
| Capital spending | -16.0K | -223.0K | -204.0K | -5.61M | -8.95M | -1.50M | -14.0M | -21.8M | -934.7K | -223.2K |
| Free cash flow | -20.8M | -29.4M | -20.2M | -26.7M | -35.8M | -27.4M | -37.3M | -50.4M | -7.34M | -6.25M |
| Cash from investing | 951.0K | 11.2M | -9.67M | 31.2M | -20.7M | -20.7M | -28.1M | -21.8M | -934.7K | -64.8K |
| Cash from financing | 11.3M | 15.4M | -907.0K | -3.27M | 29.6M | 47.2M | 22.0M | 92.3M | 23.7M | 28.0M |
| Dividends paid | -718.0K | -738.0K | ||||||||
| Share buybacks | 0 | 0 | -278.0K | -3.27M | 0 | |||||
| Change in cash | -7.84M | -3.62M | -30.0M | 8.41M | -18.4M | 3.44M | -30.6M | 40.7M | 16.4M | 22.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Sep 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 14, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 29, 2026 | Current report | SEC |
| 25-NSE | Jun 23, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jun 2, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 18, 2026 | Big-stake notice | SEC |
| 20-F · Annual report | May 15, 2026 | Annual report | SEC |
| D | Apr 28, 2026 | Other filings | SEC |
All 157 filings
Cap table
Built by 6ix from CASI Pharmaceuticals, Inc.’s releases
- Common shares
- 20,555,873
- Fully diluted
- 20,555,873
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 20,555,873 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 20,555,873 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Huang Other companies: Connect Biopharma Holdings Limited (Founding Partner of Panacea Venture · Since at least Mar 18, 2026); Atara Biotherapeutics, Inc. (Human Capital · Since at least May 16, 2025); Orion Biotech Opportunities Corp (Chief Executive Officer, Director · May 12, 2021 – May 17, 2023 · Past); Alaunos Therapeutics, Inc. (Director · Jul 20, 2020 – Jun 6, 2023 · Past); Windtree Therapeutics, Inc. (Director · Dec 21, 2018 – Feb 22, 2023 · Past) | Director · Since at least Mar 18, 2026 |
| Alexander A Zukiwski Other companies: Arno Therapeutics Inc (Chief Executive Officer & CMO, Director · Jan 25, 2013 – Apr 7, 2016 · Past) | Global Chief Medical Officer · Since at least Mar 18, 2026 |
| Thomas Folinsbee Other companies: Xynomic Pharmaceuticals Holdings Inc (Director · Jun 19, 2017 – Jun 19, 2017 · Past) | Director · Since at least Mar 18, 2026 |
| Alex Wu | Director · Since at least Mar 18, 2026 |
| Alex Wu | Director · Since at least Nov 4, 2026 |
| Barbara Helene Hannelore Krebs-Pohl | Director · Since at least Mar 18, 2026 |
| Chunhua Wang | Chief Operating Officer · Since at least Mar 18, 2026 |
| Frank Su | Director · Since at least Nov 4, 2026 |
| Hai Huang | Global Chief Commercial Ofcr · Since at least Mar 18, 2026 |
| Junping Chen | Chief Medical Officer · Since at least Nov 5, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Kun Qian | Global Controller · Since at least Mar 18, 2026 |
| Wei Gao | General Counsel · Since at least Mar 18, 2026 |
| Wei-Wu He | Executive Chairman · Since at least Mar 18, 2026 |
| Xuebo Zeng | Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about CASI Pharmaceuticals, Inc.